Proactive Investors - Run By Investors For Investors

E-Therapeutics chief says drug candidate has hit a “sweet spot”

E-Therapeutics (LON:ETX) chief executive Malcolm Young tells Proactive that the firm has hit the “sweet spot” on the drug candidate ETS6103 following its latest test results.

The Phase IIb study, which was a larger study at a lower dose showed the drug was a little bit off the efficacy of its rival amitriptyline, but was still effective.

But the firm has previously completed a Phase IIa study on ETS6103, which was carried out on a small number of patients at a higher dose, showing the drug had the same efficacy as its closest rival.

Young says that the drug has a “cleaner profile” than amitriptyline, and adds that “across the two studies, we are pleased.”

Meet Avation PLC, CUI Global, ReNeuron Group Plc, Carnarvon Petroleum and BOS GLOBAL HOLDINGS at our event, London, 23 February 2017. Register here »
Why Invest In e-Therapeutics plc? Read More Here

Register here to be notified of future e-Therapeutics plc articles
View full ETX profile

e-Therapeutics plc Timeline

September 20 2016

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.